Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a new drug combo beat elephantiasis?

NCT ID NCT04410406

Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a drug called moxidectin, combined with other medicines, works better than the standard treatment (ivermectin combinations) for lymphatic filariasis, a parasitic disease that can cause severe swelling. 164 adults with the infection received a single dose of one of four drug combinations. Researchers checked blood samples over 36 months to see if the parasites were cleared. The goal is to find a more effective single-dose treatment to help control and eventually eliminate the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Moxidectin (Mox) 8 mg, Ivermectin (IVM) 200 µg/kg, Diethylcarbamazine (DEC) 6 mg/kg, Albendazole (ABZ) 400 mg
What this could lead to
If moxidectin combinations work better, this could offer a more effective single-dose treatment for lymphatic filariasis, reducing transmission and disease burden.
What could go wrong
This is a completed Phase 3 trial with 164 participants, so results are available but may not apply to all populations. The drugs can cause side effects like dizziness or allergic reactions, and long-term benefits are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

164 people

The number who actually took part.

Started

Aug 2020

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provision of signed and dated informed consent form * Male or female, aged 18-70 years * In good general health as evidenced by medical history * Peripheral night blood W. bancrofti Mf levels ≥40 Mf/mL * No history of taking antifilarial medications in past 12 months * Resident of the study area with no plans to change residence in the next 36 months * For women of childbearing potential, willing to use appropriate method of contraception for one month following each treatment Exclusion Criteria: * Pregnancy or currently breastfeeding * Known allergic reactions to any of the study medications * Evidence of severe or systemic comorbidities (aside from features of filarial disease), as judged by the principal investigator * Baseline biochemical abnormalities, as indicated by AST, ALT, or creatinine \> 2 times the upper limit of normal * Evidence of urinary tract infection as indicated by 3+ nitrites on dipstick (individuals with 1+ or 2+ nitrites will not be excluded) or underlying chronic kidney disease as indicated by 3+ protein or 3+ blood on urine dipstick exam * Hgb \< 7 gm/dL (any such individuals will be referred to the local health center for evaluation and treatment) * Positive skin snip for onchocerciasis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphatic filariasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

filarial elephantiasis filariasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphatic filariasis

Contacts and locations

Locations

  • Regional Hospital of Agboville, Southern Cote d'Ivoire

    Agboville, Côte d’Ivoire

More trials for these conditions

Other studies related to the condition(s) this trial covers.